These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 35598367)

  • 1. Natural PPARs agonists for the treatment of nonalcoholic fatty liver disease.
    Pan J; Zhou W; Xu R; Xing L; Ji G; Dang Y
    Biomed Pharmacother; 2022 Jul; 151():113127. PubMed ID: 35598367
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Peroxisome Proliferator-Activated Receptors and Their Novel Ligands as Candidates for the Treatment of Non-Alcoholic Fatty Liver Disease.
    Fougerat A; Montagner A; Loiseau N; Guillou H; Wahli W
    Cells; 2020 Jul; 9(7):. PubMed ID: 32650421
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Review. The role of peroxisome proliferator-activated receptor in the treatment of non-alcoholic fatty liver disease.
    Sun X; Zhang Y; Xie M
    Acta Pharm; 2017 Mar; 67(1):1-13. PubMed ID: 28231052
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nonalcoholic steatohepatitis: the role of peroxisome proliferator-activated receptors.
    Francque S; Szabo G; Abdelmalek MF; Byrne CD; Cusi K; Dufour JF; Roden M; Sacks F; Tacke F
    Nat Rev Gastroenterol Hepatol; 2021 Jan; 18(1):24-39. PubMed ID: 33093663
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nuclear receptors and nonalcoholic fatty liver disease.
    Cave MC; Clair HB; Hardesty JE; Falkner KC; Feng W; Clark BJ; Sidey J; Shi H; Aqel BA; McClain CJ; Prough RA
    Biochim Biophys Acta; 2016 Sep; 1859(9):1083-1099. PubMed ID: 26962021
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Roles of the peroxisome proliferator-activated receptors (PPARs) in the pathogenesis of nonalcoholic fatty liver disease (NAFLD).
    Qiu YY; Zhang J; Zeng FY; Zhu YZ
    Pharmacol Res; 2023 Jun; 192():106786. PubMed ID: 37146924
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Crosstalk between PPARs and gut microbiota in NAFLD.
    Wu L; Li J; Feng J; Ji J; Yu Q; Li Y; Zheng Y; Dai W; Wu J; Guo C
    Biomed Pharmacother; 2021 Apr; 136():111255. PubMed ID: 33485064
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PPARs and nonalcoholic fatty liver disease.
    Liss KH; Finck BN
    Biochimie; 2017 May; 136():65-74. PubMed ID: 27916647
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Roles of PPARs in NAFLD: potential therapeutic targets.
    Tailleux A; Wouters K; Staels B
    Biochim Biophys Acta; 2012 May; 1821(5):809-18. PubMed ID: 22056763
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Role of Nuclear Receptors in the Pathophysiology, Natural Course, and Drug Treatment of NAFLD in Humans.
    Ballestri S; Nascimbeni F; Romagnoli D; Baldelli E; Lonardo A
    Adv Ther; 2016 Mar; 33(3):291-319. PubMed ID: 26921205
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modulation of xenobiotic nuclear receptors in high-fat diet induced non-alcoholic fatty liver disease.
    Li X; Wang Z; Klaunig JE
    Toxicology; 2018 Dec; 410():199-213. PubMed ID: 30120929
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-NASH Drug Development Hitches a Lift on PPAR Agonism.
    Boeckmans J; Natale A; Rombaut M; Buyl K; Rogiers V; De Kock J; Vanhaecke T; M Rodrigues R
    Cells; 2019 Dec; 9(1):. PubMed ID: 31877771
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Role of Nuclear Receptors in the Pathogenesis and Treatment of Non-alcoholic Fatty Liver Disease.
    Yang Z; Danzeng A; Liu Q; Zeng C; Xu L; Mo J; Pingcuo C; Wang X; Wang C; Zhang B; Zhang B
    Int J Biol Sci; 2024; 20(1):113-126. PubMed ID: 38164174
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transcriptional Regulation of Metabolic Pathways via Lipid-Sensing Nuclear Receptors PPARs, FXR, and LXR in NASH.
    Cariello M; Piccinin E; Moschetta A
    Cell Mol Gastroenterol Hepatol; 2021; 11(5):1519-1539. PubMed ID: 33545430
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nuclear Receptors Linking Metabolism, Inflammation, and Fibrosis in Nonalcoholic Fatty Liver Disease.
    Puengel T; Liu H; Guillot A; Heymann F; Tacke F; Peiseler M
    Int J Mol Sci; 2022 Feb; 23(5):. PubMed ID: 35269812
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PPAR agonists reduce steatosis in oleic acid-overloaded HepaRG cells.
    Rogue A; Anthérieu S; Vluggens A; Umbdenstock T; Claude N; de la Moureyre-Spire C; Weaver RJ; Guillouzo A
    Toxicol Appl Pharmacol; 2014 Apr; 276(1):73-81. PubMed ID: 24534255
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Peroxisome Proliferator-Activated Receptors and Their Agonists in Nonalcoholic Fatty Liver Disease.
    Choudhary NS; Kumar N; Duseja A
    J Clin Exp Hepatol; 2019; 9(6):731-739. PubMed ID: 31889755
    [TBL] [Abstract][Full Text] [Related]  

  • 18. RLA8-A New and Highly Effective Quadruple PPAR-
    Li MH; Chen W; Wang LL; Sun JL; Zhou L; Shi YC; Wang CH; Zhong BH; Shi WG; Guo ZW
    J Pharmacol Exp Ther; 2019 Apr; 369(1):67-77. PubMed ID: 30745416
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of peroxisome proliferator-activated receptors in non-alcoholic fatty liver disease inflammation.
    Silva AKS; Peixoto CA
    Cell Mol Life Sci; 2018 Aug; 75(16):2951-2961. PubMed ID: 29789866
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Target Deconvolution of Fenofibrate in Nonalcoholic Fatty Liver Disease Using Bioinformatics Analysis.
    Mahmoudi A; Butler AE; Jamialahmadi T; Sahebkar A
    Biomed Res Int; 2021; 2021():3654660. PubMed ID: 34988225
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.